Should lCU COVID-19 patients empirically receive therapeutic doses of anticoagulant?

Should lCU COVID-19 patients empirically receive therapeutic doses of anticoagulant? Infez Med. 2020 Jun 01;28(suppl 1):52-56 Authors: Di Perri G Abstract In spite of many ongoing attempts to repurpose existing antivirals, no drugs have emerged yet with the desirable activity against SARS-CoV-2. Hydroxychloroquine, lopinavir/ritonavir, remdesivir, umifenovir, favipiravir, ribavirin and beta-interferon-1 gave rise to variable but still inconsistent proof of clinical efficacy in the treatment of COVID-19. Pathogenetic studies have shown significant differences between commonly defined viral pneumonia and COVID-19 pulmonary disease. In severe forms, immune/inflammatory alterations reminiscent of disease forms like Macrophage Activation Syndrome (MAS) have been described, and therapeutic options other than anti-infective have been proposed and implemented, such as anti-inflammatory and anticoagulative agents. The thrombotic phenomena described in the pulmonary vascular bed of patients with severe COVID-19 suggest the administration of low-molecular weight heparin (LMWH) as standard measure in hospitalized patients with COVID-19. PMID: 32532939 [PubMed - as supplied by publisher]
Source: Infezioni in Medicina - Category: Infectious Diseases Tags: Infez Med Source Type: research